Startup profile · funding coverage
Alpine Bio
Biomanufacturing platform producing animal-free dairy proteins via engineered plants.
Stage
series b
Status
private
Coverage
full
Why Alpine Bio is interesting
Alpine Bio (ex-Nobell) scales casein without cows — a16z bio bet alongside Pear and ag-focused syndicate.
Key facts
- Series B (2021): $75M with a16z, Pear VC, AgFunder participation (AgFunderNews)
- Formerly Nobell Foods — plant-based casein via molecular farming
Investors in our directory
Funds linked from Alpine Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Climate Tech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Alpine Bio's financing or category context.
FAQs about Alpine Bio
Funding context and why this company shows up in venture coverage.
Alpine Bio grows dairy proteins (notably casein) in engineered plants — animal-free ingredients for cheese and dairy alternatives via molecular farming.
a16z and Pear VC participated in the $75M Series B (2021). See /fund/andreessen-horowitz and /fund/pear-vc.
Series B private company after the 2021 $75M round; formerly known as Nobell Foods.
Plant-based dairy often lacks functional casein for real cheese texture. Alpine's molecular-farming thesis targets ingredient parity without fermentation vats or cows.
No — remains private as of July 2026.
Last updated: 2026-07-24